Dr. Reddy’s and Prestige BioPharma comes together to supply and commercialize Trastuzumab biosimilar in Latin American and Southeast Asian countries
Dr. Reddy’s Laboratories Ltd. and Prestige BioPharma Ltd. announced on Thursday that they have signed a binding agreement for the supply and commercialization of Prestige BioPharma’s proposed trastuzumab biosimilar in specified Latin American and Southeast Asian countries.
“In keeping with our purpose of accelerating access to affordable and innovative medicines, we are happy to bring this life-saving drug to patients in need. Our partnership with Prestige BioPharma will help us combine their established expertise in the area of biosimilars with our commercial strengths and growth ambition in these markets. This is in line with our stated intention to create a portfolio of oncology products and expand our biosimilar offerings in Emerging Markets.”M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy’s
As per the terms of the license agreement, Dr. Reddy’s will have exclusive rights to market the proposed biosimilar in Latin America and Southeast Asia. Under the partnership, Prestige BioPharma will be responsible for the sustainable commercial supply of HD201 from its manufacturing facilities in Osong, South Korea, while Dr. Reddy’s will be in charge of local registrations, marketing, and sales in the licensed areas.
“We are delighted to establish a partnership with Dr. Reddy’s for key Latin American and Southeast Asian markets. Dr. Reddy’s is the ideal partner to commercialize our lead biosimilar in these territories. With this collaboration, we look forward to further strengthening the value of our biosimilar programs in global markets.”Lisa S. Park, CEO of Prestige BioPharma
Trastuzumab (HD201) from Prestige BioPharma is a proposed biosimilar to Roche’s Herceptin, used for the treatment of HER2-positive breast cancer and metastatic gastric cancer. Trastuzumab targets human epidermal growth factor 2 (HER2) and inhibits the development of cancer cells by attaching specifically to the protein HER2. HER2 is overexpressed in some types of cancer cells, which promotes cancer cell development.